For billions of years, viruses called bacteriophages have been waging war on bacteria — and winning. Now researchers at Caltech and the University of Toronto have decoded one of their most powerful weapons: a protein called RIP1 that punches lethal holes in bacterial cell membranes, killing even drug-resistant strains that current antibiotics cannot touch. The discovery points toward a new class of therapies that could be engineered to mimic the viral attack.
Bacteriophages — phages for short — are viruses that infect only bacteria. They are everywhere: in soil, in the ocean, on the surfaces of plants, inside the human gut. There are estimated to be more phages on Earth than all other organisms combined. For every bacterial species, there are phages that have evolved specifically to destroy it — a billion years of co-evolutionary arms race compressed into an astonishing biological toolkit.
**Meet RIP1: The Sensor-Triggered Pore**
The Caltech and University of Toronto team focused on a protein they named RIP1 — ring-interacting pore 1. What makes RIP1 remarkable is that it functions as a sensor: it sits dormant until it detects specific viral proteins, essentially a signal that infection of the bacterial host is proceeding as intended.
When RIP1 detects that signal, it activates. It assembles itself into a ring-shaped structure and punches a pore through the bacterial cell membrane — the lipid bilayer that holds the bacterium together and regulates everything that moves in or out. Once that membrane is perforated, the bacterium can no longer maintain its internal chemistry. It leaks, loses integrity, and dies.
Critically, RIP1's mechanism of action is entirely independent of antibiotic resistance mechanisms. It doesn't matter whether the bacterium has evolved to neutralise penicillin, vancomycin, carbapenem, or any other antibiotic. The cell membrane is still there. And RIP1 can still punch through it.
**Why Multi-Drug Resistant Bacteria Are So Dangerous**
The WHO has identified antimicrobial resistance as one of the top ten global public health threats facing humanity. Projections suggest that if current trends continue, drug-resistant infections could kill 10 million people per year by 2050 — more than cancer kills today.
This is why discoveries like RIP1 matter so much. An attack mechanism that bypasses resistance entirely is inherently more durable than another antibiotic that resistance can simply evolve around.
**A Platform for Engineered Therapies**
The research team proposes that RIP1 can serve as a scaffold — a design template — for engineered antimicrobial agents that mimic its mechanism. Rather than using phages themselves (which can be difficult to manufacture and deliver consistently), synthetic variants of RIP1-like proteins could potentially be designed to target specific bacterial species with high precision.
A separate Caltech team, working in parallel, identified a complementary mechanism: a protein called MurJ that locks bacterial cell wall construction into an inactive position, causing bacteria to die. Between RIP1's membrane-punching and MurJ's wall-construction block, the phage weapons cabinet is revealing itself to be richer and more varied than scientists previously appreciated.
Understanding RIP1 also advances the broader field of phage therapy — using carefully selected phages to treat bacterial infections directly. Phage therapy has already been used in compassionate-use cases to save the lives of patients with infections that had exhausted all other treatment options. Drug-resistant infections currently kill 1.27 million people per year worldwide. RIP1 is one piece of the emerging answer. 🦠🔬
*Sources: Caltech News · University of Toronto · EurekaAlert · Science Daily · World Health Organization (AMR fact sheet)*
